Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:51 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1057–1080 of 25,190 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: PRE Clear all

Conditions: Smoking Cessation
Interventions: Mindfulness with Contingency Management, Active Control; Behavioral
Lead sponsor: Fordham University; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Pre-Eclampsia, Hypertension in Pregnancy, Pregnancy Complications, Hypertension, Pregnancy-Induced
Interventions: Furosemide, Placebo; Drug · Other
Lead sponsor: Melanie Maykin, MD; Other
Eligibility: 18 Years and older · Female only
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Honolulu, Hawaii

Conditions: Acute Respiratory Distress Syndrome, Ventilation Perfusion Mismatch
Interventions: Nitric Oxide; Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 80 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Von Willebrand Disease, Type 3
Interventions: Emicizumab, von Willebrand Factor (VWF) Concentrates, Factor VIII (FVIII) Concentrates, von Willebrand Factor (VWF) and Factor VIII (FVIII) Concentrates, Bypassing Agents; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 1 Month and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 6
States / cities: Sacramento, California • Gainesville, Florida • Lexington, Kentucky + 3 more

Conditions: Acquired Thrombotic Thrombocytopenic Purpura
Interventions: Caplacizumab, Placebo; Biological
Lead sponsor: Ablynx, a Sanofi company; Industry
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 13
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Atlanta, Georgia + 10 more

Conditions: Brain Cancer, Brain Metastases, Melanoma, Lung Cancer, Breast Cancer, HER2-positive Breast Cancer, Colorectal Cancer, Gastrointestinal Cancer, SRS, SRT, Whole Brain Radiation, Stereotactic Radiation, AGuIX, Nanoparticle, Cystic, Brain Tumor
Interventions: Stereotactic Radiation, AGuIX gadolinium-based nanoparticles, Placebo; Radiation · Drug · Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Intracranial Aneurysm
Interventions: Embolization of intracranial aneurysm; Device
Lead sponsor: Tennessee Neurovascular Institute, LLC; Other
Eligibility: 18 Years to 80 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Knoxville, Tennessee

Conditions: Clostridium Difficile, Clostridium Difficile Infection, C Difficile Colitis
Interventions: fluoroquinolone preprescription authorization, Control; Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: Not listed
Enrollment: 5,871 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 7
States / cities: Phoenix, Arizona • Moreno Valley, California • Rochester, Minnesota + 4 more

Conditions: Alcoholism
Interventions: Quantity Frequency Model, Targets Subjective Drunkenness; Behavioral
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 333 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Hematologic Neoplasms
Interventions: Not listed
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Depression
Interventions: Mifepristone, Placebo Oral Capsule; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 1
States / cities: Stanford, California

Conditions: Neoplasm Metastasis, Central Nervous System Metastases
Interventions: Intensity Modulated Radiotherapy; Radiation
Lead sponsor: New Mexico Cancer Research Alliance; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Clonal Cytopenia of Undetermined Significance, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Hodgkin Lymphoma, Recurrent Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Lymphoma, Chronic Myelomonocytic Leukemia
Interventions: Ascorbic Acid, Carboplatin, Cisplatin, Cytarabine, Dexamethasone, Etoposide, Gemcitabine Hydrochloride, Ifosfamide, Laboratory Biomarker Analysis, Oxaliplatin, Placebo Administration, Questionnaire Administration, Rituximab, Decitabine, Biospecimen Collection, Core Biopsy, Bone Marrow Aspiration, Bone Marrow Biopsy, Echocardiography, Positron Emission Tomography, Magnetic Resonance Imaging, Central Venous Cannula Insertion, Portacath Placement, Computed Tomography, Decitabine and Cedazuridine; Dietary Supplement · Drug · Other + 2 more
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2033
U.S. locations: 4
States / cities: Mankato, Minnesota • Rochester, Minnesota • Eau Claire, Wisconsin + 1 more

Conditions: Hepatitis C, HIV, AIDS, Substance Use
Interventions: Control Group, Care Facilitation Group; Other · Behavioral
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 422 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 11
States / cities: Birmingham, Alabama • Torrance, California • Miami, Florida + 8 more

Conditions: Uterine Cervical Neoplasms
Interventions: Cognitive-affective barriers counseling, Cognitive-affective barriers counseling via brochure, standard care; Behavioral
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 211 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Suicidal Ideation, Suicidal and Self-injurious Behavior, Suicide, Autism Spectrum Disorder
Interventions: Safety Planning Intervention tailored for Autistic Individuals, Safety Planning Intervention Tailored for Autistic Individuals Plus Structured Follow-Up Contacts; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 12 Years to 99 Years
Enrollment: 1,665 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 5
States / cities: Baltimore, Maryland • Chapel Hill, North Carolina • Columbus, Ohio + 2 more

Conditions: Patient Satisfaction
Interventions: Telehealth 2 week postoperative visit; Other
Lead sponsor: Jackson, Elisha; Other
Eligibility: 18 Years and older · Female only
Enrollment: 142 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Stroke
Interventions: New Repetitive Magnetic Stimulation (rTMS) Approach, Conventional Repetitive Magnetic Stimulation (rTMS) Approach; Device
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 90 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Pancreatic Ductal Adenocarcinoma
Interventions: The risk assessment questionnaire, Blood specimens, tumor tissue samples will be requested; Behavioral · Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 21 Years and older
Enrollment: 600 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2026
U.S. locations: 10
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 6 more

Conditions: Sleep Onset Latency
Interventions: Amber Tinted Glasses, Clear Glasses, Smart Lightbulbs; Device
Lead sponsor: University of Arizona; Other
Eligibility: 60 Months to 83 Months
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Healthy
Interventions: Placebo Beverage, 2.8 g Sustamine Beverage, 19.6 g Sustamine Beverage; Dietary Supplement
Lead sponsor: University of Texas at Austin; Other
Eligibility: 20 Years to 45 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Multiple Myeloma
Interventions: 89Zr-daratumumab PET/CT; Drug
Lead sponsor: Hoag Memorial Hospital Presbyterian; Other
Eligibility: 21 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 2
States / cities: Irvine, California • Miami, Florida

Conditions: Denture Retention
Interventions: Denture Adhesive Cream (Conventional Application), Denture Adhesive (Continuous Strip Application), No Adhesive; Device · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Fort Wayne, Indiana

Conditions: Lung Cancer
Interventions: carboplatin, paclitaxel; Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 584 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2006
U.S. locations: 35
States / cities: La Jolla, California • San Francisco, California • Wilmington, Delaware + 24 more

Search by objective public record fields.

Smoking Cessation Intervention for Smokers With Depression Receiving Outpatient Psychiatric Treatment

Furosemide vs. Placebo for Severe Antepartum Hypertension

Vascular ARDS Recruitment After Inhaled Nitric Oxide

A Study to Assess the Efficacy and Safety of Emicizumab in Participants With Type 3 Von Willebrand Disease

Study to Assess Efficacy and Safety of Anti-von Willebrand Factor (vWF) Nanobody in Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)

Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases

Prospective Packing Density With Target Coils I

FQ Restriction for the Prevention of CDI

The Teachable Moment: Screening and Brief Intervention for Admitted Trauma Patients

Feasibility Study of Genomic Sequencing to Find Potential Targets for Personalized Therapy

Mifepristone Treatment for Patients With Non-psychotic Major Depressive Disorder Receiving Bilateral ECT

Whole Brain Radiation Using IMRT for Patients With Brain Metastases

Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia

Assessing Long-term CTN 0049 Outcomes, HCV Prevalence and Progression Along the HCV Care Continuum Among HIV/HCV Co-infected Substance Users in the U.S.

Facilitating Follow-Up Adherence for Abnormal Pap Smears

A Comparison of Two Brief Suicide Prevention Interventions Tailored for Youth on the Autism Spectrum

Telehealth Postop Follow up RCT

A Novel Approach for Brain Stimulation in Severe Stroke

A Registry for BRCA Mutation Carriers With Pancreatic Ductal Adenocarcinoma

Circadian Light Exposure Adjustment for Restfulness

Effects of Sustamine(TM) on Cycling Time Trial Performance

A Diagnostic Study of CD38-Targeted ImmunoPET of Myeloma

A Study to Investigate a Method to Measure Food Occlusion by Denture Adhesives in Denture Wearers

Paclitaxel With or Without Carboplatin in Treating Patients With Advanced Non-small Cell Lung Cancer